Silexion Therapeutics (SLXN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Silexion Therapeutics Corp  (NASDAQ: SLXN)


Silexion Therapeutics's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Silexion Therapeutics's ROA in the second quarter of 2026?
Silexion Therapeutics Corp achieved a return on average assets (ROA) of 99.09 % in its second quarter of 2026, which is below Silexion Therapeutics's average return on assets, which stands at 157.47%.

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 9 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 22, from total ROA ranking in the first quarter of 2026 at 37.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -26.76 % -44.61 % 215.75 % 276.22 % 155.49 %
Y / Y Net Income Change - 57.52 % - -72.52 % -
Net Income (TTM) in million 7 13 12 6 14
Return On Assets (TTM) 99.09 % 176.68 % 144.68 % 82.17 % 294.91 %
SLXN's Total Ranking # 22 # 37 # 45 # 19 #
Total Assets (TTM) in million 4 5 7 12 6
Seq. Total Assets Change -7.74 % -36.22 % -37.88 % 100.35 % -30.22 %
Seq. Net Income Change - -38.06 % 35.25 % 30.32 % 44.27 %

SLXN's 5 Years Annual ROA >> Back to SLXN Management Effectiveness >> Compare SLXN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 2
Sector # 10
Overall # 37

Return On Assets Statistics
High Average Low
286.41 %
157.47 %
80.51 %
(Jun 30 2025)   (Sep 30 2025)





Financial Statements
Silexion Therapeutics's Assets $ 4 million SLXN's Balance sheet
Silexion Therapeutics's Income $ -4 million Quarterly SLXN's Income Statement
SLXN's Income by Division See SLXN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024
FY
FY
FY
Y / Y Total Assets Change 195.23 % - - - -
Total Assets in million 7 2 0 0 0
Y / Y Net Income Change -28.22 % - - - -
Net Income in million 12 17 0 0 0
Annual Return On Assets 176.58 % 726.26 % - - -

SLXN's 5 Years Annual ROA >> Back to SLXN Management Effectiveness >> Compare SLXN ROA to its Competitors



Comment on SLXN's ROA in the fiscal year ending 2025
In the fiscal year 2025 Silexion Therapeutics's ROA decreased compared to previous year to 176.58 %, due to deterioration of net income -28.22 % to $11.91 million, from $16.60 million a year ago, as SLXN's assets were $6.75 million.


More Return On Assets Ratios
SLXN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SLXN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SLXN's Competitors
Subscribers only: Roa for Silexion Therapeutics's Suppliers
Subscribers only: Return On Assets for SLXN's Customers

You may also want to know
SLXN's Roi SLXN's Inventory Turnover Ratio SLXN's Growth Rates SLXN's Dividend Comparisons
SLXN's Profitability Ratios SLXN's Asset Turnover Ratio SLXN's Dividend Growth
SLXN's Roe SLXN's Valuation Ratios SLXN's Financial Strength Ratios SLXN's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Kyntra Bio Inc   156.80 %
Vor Biopharma Inc   154.23 %
Glucotrack Inc   151.40 %
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %

Date modified: 2026-09-08T15:11:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.